drugset
drugset / Trial / NCT07261644

A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)

NCT07261644 ↗

Phase 3 Recruiting 500 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of 608 in patients with AS.

Timeline

Start
2025-11-07
Primary completion
2027-01-14
Completion
2027-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject 608 Unknown — Subcutaneous

Indications

ankylosing spondylitis